Facts and Fictions About [18F]FDG versus Other Tracers in Managing Patients with Brain Tumors: It Is Time to Rectify the Ongoing MisconceptionsAn Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic MalignanciesMolecular Imaging Assessment of Androgen Deprivation Therapy in Prostate CancerMolecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2- [18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers18F-FDG Versus Non-FDG PET Tracers in Multiple MyelomaRole of Molecular Imaging with PET/MR Imaging in the Diagnosis and Management of Brain TumorsFibroblast Activation Protein Inhibitor TheranosticsPET-CTBased Quantitative Parameters for Assessment of Treatment Response and Disease Activity in Cancer and Noncancerous DisordersPositron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such SettingsNonmalignant Thoracic Disorders: An Appraisal of Fluorodeoxyglucose and Non>fluorodeoxyglucose PET/Computed Tomography ApplicationsFluorodeoxyglucose PET/Computed Tomography in Evaluation of Prosthetic Joints and Diabetic Foot: A Comparative Perspective with Other Functional Imaging ModalitiesUtility of PET/Computed Tomography in Infection and Inflammation ImagingRole of Fluorodeoxyglucose-PET in Interventional Radiology

In this issue, guest editors bring their considerable expertise to this important topic. Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.